MEDICURE INC
MEDICURE INC (MCUJF): 2 pipeline candidates · 2 upcoming catalysts · ~18 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.6 months
D/E 0.48 · 0% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~136d
N/A
A transparent, data-derived signal for MEDICURE INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.6M
Cash
$7.2M
Quarterly Burn
$1.7M
Runway
17.6 mo
Revenue
$5.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (2 candidates)
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in MEDICURE INC's pipeline?
MEDICURE INC (MCUJF) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MEDICURE INC's lead drug candidate?
MEDICURE INC's most advanced tracked candidate is pyridoxal (Phase 3) for Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency.
What is MEDICURE INC's next catalyst?
MEDICURE INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency" — expected November 1, 2026.
What is MEDICURE INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MEDICURE INC has approximately 17.6 months of cash runway.
What is MEDICURE INC's market capitalization?
MEDICURE INC's market capitalization is approximately $7.6M.
Get the full picture on MEDICURE INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.